Efficacy News and Research

RSS

Asterias’ Phase 1/2a study evaluates dose escalation of AST-OPC1 for cervical spinal cord injury

Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Data Monitoring Committee has reviewed the initial safety data from all three patients in the first cohort and has recommended dose escalation to the second cohort.

20 Oct 2015

Leading obesity groups stress need to regulate weight-loss dietary supplements

On the heels of a new study tying dietary supplements to more than 23,000 emergency room visits each year, four leading obesity research, treatment and prevention groups issue a joint scientific statement recommending dietary supplements for weight loss claiming curative or medicinal qualities be subject to review and approval by the United States Food and Drug Administration (FDA).

20 Oct 2015

Negative stereotypes have adverse effects on patients' health

A national study led by a USC researcher found people who encountered the threat of being judged by negative stereotypes related to weight, age, race, gender, or social class in health care settings reported adverse effects.

20 Oct 2015

First patients receive doses of antisense drug for Huntington's disease

The first few patients have received doses of an experimental RNA-targeting drug for Huntington's disease, it was announced today.

20 Oct 2015

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21.

20 Oct 2015

APBI brachytherapy improves overall survival in selected patients with early stage breast cancer

The Groupe Européen de Curiethérapie European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) today announced results from a prospective, randomized, multicenter phase III study comparing accelerated partial breast irradiation (APBI) with interstitial multicatheter brachytherapy to whole breast irradiation (WBI).

20 Oct 2015

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

In the UK there are currently over 3.5 million people who have diabetes, with a growth rate exceeding 280,000 people per year. Diabetic retinopathy is the most common complication of diabetes.

19 Oct 2015

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

TARSA Therapeutics, Inc. today announced that its New Drug Application (NDA) for TBRIATM (calcitonin-salmon [rDNA origin] delayed release tablets) submitted to the U.S. Food and Drug Administration (FDA) in July 2015, has been accepted for review, with a PDUFA date of May 30, 2016.

19 Oct 2015

NCCN reveals new value initiative for CML and Multiple Myeloma

The National Comprehensive Cancer Network, a not-for-profit alliance of 26 of the world's leading cancer centers, today unveiled its new value initiative—the NCCN Evidence Blocks, published within new versions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Chronic Myelogenous Leukemia (CML) and Multiple Myeloma.

19 Oct 2015

UAMS researchers report positive results from treating Metastatic Merkel-cell carcinoma with idelalisib drug

Identifying a patient's genetic mutation led University of Arkansas for Medical Sciences (UAMS) physician-researcher Ling Gao, M.D., Ph.D., to an existing drug that eliminated the patient's stage IV Merkel-cell carcinoma. Gao's findings, made in collaboration with two other UAMS researchers, were published today in The New England Journal of Medicine.

19 Oct 2015

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer's offenses. Writing in the journal Scientific Reports, researchers led by a group from the Roswell Park Cancer Institute Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things, inhibiting cancer growth at the same time that they enhance the tumor-killing powers of other immune cells.

19 Oct 2015

Antibiotic resistance potentially threatens the safety and efficacy of surgical procedures and immunosuppression therapies

This week The Lancet Infectious Diseases journal published the strongest evidence to date that increasing antibiotic resistance could have disastrous consequences for patients undergoing surgery or cancer chemotherapy. Based on a review of published literature, researchers predict that a 30% reduction in the efficacy of the prophylactic antibiotics routinely given when these procedures are performed could result in 120,000 more infections and 6300 infection-related deaths every year in the USA alone.

16 Oct 2015

GATE opens for generic equivalent to glatiramer acetate in MS

Findings from the GATE study have shown equivalent efficacy and tolerability for a generic version of glatiramer acetate to that of the original brand version in the treatment of relapsing–remitting multiple sclerosis.

15 Oct 2015

New approaches to treating amblyopia

Amblyopia, commonly known as "lazy-eye," has been classically treated by patching the strong eye to force the weaker eye to be used. However, the concept of binocular dysfunction, in which the brain suppresses the image from the weaker eye in favor of the stronger eye, has motivated new approaches to amblyopia treatment.

15 Oct 2015

Poorly-designed animal study threatens validity of preclinical research

Badly designed studies may lead to the efficacy of drugs being overestimated and money being wasted on trials that prove fruitless, according to new a study from McGill University in Canada.

15 Oct 2015

CWRU investigator receives $2.82 million NIH grant to make stealth bombs for brain cancer treatment

A Case Western Reserve University researcher has received a 5-year, $2.82 million National Institutes of Health grant to make, in essence, stealth bombs that slip past the brain's defenses to attack an incurable form of cancer.

15 Oct 2015

TxCell reviews its manufacturing strategy to focus on R&D and strategic partnerships - its core, high added value businesses

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it is operating a strategic review that should result in the outsourcing of all existing and future clinical and commercial manufacturing operations to contract manufacturing organizations (CMOs).

15 Oct 2015

LEADERS FREE clinical trial demonstrates superior safety, efficacy for BioFreedom compared with bare-metal stent

Biosensors International Group, Ltd., a developer, manufacturer and marketer of innovative medical devices, announced today that the LEADERS FREE clinical trial demonstrated superior safety and efficacy for BioFreedom compared with a bare-metal stent (BMS).

15 Oct 2015

Retail health clinics best used as backup alternative to patient's primary care physician, ACP says

The American College of Physicians today said that retail health clinics - now commonly present in drugstores and/or big box retailers - are best used as a backup alternative to a patient's primary care physician for the diagnosis and treatment of episodic minor illnesses.

14 Oct 2015

Sense oligonucleotide antidote reverses actions of antisense antithrombotic drug, prevents bleeding

Researchers from Isis Pharmaceuticals (Carlsbad, CA) and Prysis Biotechnologies (Pudong, Shanghai, China) have demonstrated proof-of-concept for using a sense oligonucleotide to undo the effects of an antisense drug, an antithrombotic agent in this novel study.

14 Oct 2015

Efficacy News and Research

Asterias’ Phase 1/2a study evaluates dose escalation of AST-OPC1 for cervical spinal cord injury

Leading obesity groups stress need to regulate weight-loss dietary supplements

Negative stereotypes have adverse effects on patients' health

First patients receive doses of antisense drug for Huntington's disease

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

APBI brachytherapy improves overall survival in selected patients with early stage breast cancer

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

NCCN reveals new value initiative for CML and Multiple Myeloma

UAMS researchers report positive results from treating Metastatic Merkel-cell carcinoma with idelalisib drug

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

Antibiotic resistance potentially threatens the safety and efficacy of surgical procedures and immunosuppression therapies

GATE opens for generic equivalent to glatiramer acetate in MS

New approaches to treating amblyopia

Poorly-designed animal study threatens validity of preclinical research

CWRU investigator receives $2.82 million NIH grant to make stealth bombs for brain cancer treatment

TxCell reviews its manufacturing strategy to focus on R&D and strategic partnerships - its core, high added value businesses

LEADERS FREE clinical trial demonstrates superior safety, efficacy for BioFreedom compared with bare-metal stent

Retail health clinics best used as backup alternative to patient's primary care physician, ACP says

Sense oligonucleotide antidote reverses actions of antisense antithrombotic drug, prevents bleeding

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News